Is Harbor profitable in 2026?

No profitability figures are public. Harbor reported roughly $187K in contracted EDC software revenue over a 12-month period plus a $1.93M three-year full-service CRO contract signed by May 2026, but these are self-reported, unaudited figures with no disclosed margins or profitability status.

Could AI replace Harbor's clinical trial services?

Unlikely soon. Harbor uses AI (Magic Build, Magic Capture) to automate transcription and database builds by about 90 percent, but keeps humans reviewing every record for 21 CFR Part 11 compliance, since frontier AI labs cannot assume FDA regulatory liability, as of May 2026.

Who is Harbor's biggest competitor?

Legacy CROs like IQVIA, ICON and Parexel dominate the $82B outsourced CRO services market Harbor targets (vendor-claimed by Harbor), while EDC vendors Medidata and Veeva compete on the software layer; Medidata alone is deployed in over 36,000 trials as of April 2026.

Who owns Harbor the AI-native CRO company?

Harbor is privately held and venture-backed, a Y Combinator Winter 2026 (P26) portfolio company co-founded by CEO Albert Cai and CTO Nathan. No priced seed round, lead investor, or valuation beyond YC's standard SAFE terms was confirmed as of May 2026.

Has Harbor had layoffs?

No layoffs have been reported. Harbor is in growth mode, having just pivoted from pure EDC software to a full-service CRO model in May 2026 and signed its first seven-figure services contract around the same time.

What does Harbor actually sell?

Harbor sells a 21 CFR Part 11-compliant electronic data capture (EDC) system plus, since May 2026, full-service CRO operations including site monitoring, query resolution, and data management, layering AI automation on top of a regulated system of record.

YC Spring 2026 · United States

Harbor

AI-native CRO that built a Part 11 EDC system and now runs full clinical trials.

Defensible for now

Assessed 27 July 2026 · Evidence as of 27 July 2026

Real protection, with named pressure against it.

On the recordSince 27 July 2026 · Checkable from late 2027 · Every call on the record Checkpoint: Delivery outcome and hours-per-trial trend on the first $1.93M full-service CRO contract

The call

Harbor has one real contract proving the model and a crowded field of AI-CRO startups chasing the same $82B market.

Harbor builds software that drug companies must use to run clinical trials under FDA rules, then layers AI tools on top to cut down paperwork and busywork. It is hard to copy because the FDA approval takes years and the liability falls on Harbor, not on big AI companies like OpenAI or Google, which means those companies cannot just build this themselves. The big old trial companies (IQVIA, ICON, Parexel) cannot compete because they make money by charging per worker, so automating those workers kills their profit. But Harbor is unproven: it has one small contract, many other YC startups are chasing the exact same idea, and the real test over the next year or two is whether trials actually run faster and cheaper with Harbor's system or whether it just looks good in a pitch deck.

Why

AI pressure: Frontier AI labs (OpenAI, Anthropic, Google) shipping document agents for clinical trial workflows. Frontier models could commoditize the AI layer, but none can carry FDA regulatory liability, so Harbor still needs a human system of record. Could AI do the core job? Only partly.

Bigger players: Medidata (Rave EDC) and Veeva, adding AI features to existing EDC platforms. Legacy EDC vendors have weaker structural blocks than CROs but no public move yet toward full-service AI-run trials. Could a giant copy it? Probably.

What protects it. Harbor holds the Part 11 compliance liability and human-in-the-loop review that both AI labs and legacy CRO billing models can't easily replicate.

What would change this call

Harbor announces a second full-service CRO contract within 12-18 months. Would show the model scales beyond the first sponsor rather than being a one-off.
Human-hours-per-trial on Harbor's next contracts stays flat or rises versus the first. Would show Harbor is a services firm with AI branding, not an automation-driven category leader.
IQVIA, ICON, or Parexel launches a fixed-fee or outcome-based pricing tier. Would show incumbents responding directly to Harbor's pricing advantage.

Key numbers

$1.93M three-year full-service CRO contract signed (2026-05-29)
7 active trials, ~$187K contracted software revenue (2026-05-29)
Part 11 EDC built in 8 months with Magic Build/Capture (2026-03-16)

Named risks

Entire full-service CRO thesis rests on delivery outcome of one $1.93M three-year contract. Severity: high
Crowded YC cohort (Phases, Astraea, fullstackcli.com) pursuing identical AI-native CRO positioning. Severity: medium
Any data-integrity incident in Part 11 regulated environment could destroy sponsor trust. Severity: high
EDC giants Medidata and Veeva face no channel conflict blocking AI bolt-on features. Severity: medium
All traction and revenue figures are self-reported by Harbor with no third-party verification. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
IQVIA / ICON / Parexel	contesting	Harbor targets their FTE-billed monitoring and data management revenue with fixed-fee AI services, May 2026
Medidata	gaining on	Medidata's Rave EDC has 36,000+ trial deployments as of April 2026 vs Harbor's 7 trials
Veeva Systems	contesting	Veeva Vault EDC positioned as modern legacy alternative, same target buyers as Harbor, April 2026
Phases	contesting	YC-backed peer offering AI trial oversight and recruitment agent, launched same 2026 window
Astraea	contesting	YC-backed peer automating biometrics, SDTM, ADaM, TFL in same 2026 cohort
fullstackcli.com	contesting	Self-described regulated agent OS for GxP systems, direct positioning overlap with Harbor, 2026

Questions people ask

Is Harbor profitable in 2026?: No profitability figures are public. Harbor reported roughly $187K in contracted EDC software revenue over a 12-month period plus a $1.93M three-year full-service CRO contract signed by May 2026, but these are self-reported, unaudited figures with no disclosed margins or profitability status.
Could AI replace Harbor's clinical trial services?: Unlikely soon. Harbor uses AI (Magic Build, Magic Capture) to automate transcription and database builds by about 90 percent, but keeps humans reviewing every record for 21 CFR Part 11 compliance, since frontier AI labs cannot assume FDA regulatory liability, as of May 2026.
Who is Harbor's biggest competitor?: Legacy CROs like IQVIA, ICON and Parexel dominate the $82B outsourced CRO services market Harbor targets (vendor-claimed by Harbor), while EDC vendors Medidata and Veeva compete on the software layer; Medidata alone is deployed in over 36,000 trials as of April 2026.
Who owns Harbor the AI-native CRO company?: Harbor is privately held and venture-backed, a Y Combinator Winter 2026 (P26) portfolio company co-founded by CEO Albert Cai and CTO Nathan. No priced seed round, lead investor, or valuation beyond YC's standard SAFE terms was confirmed as of May 2026.
Has Harbor had layoffs?: No layoffs have been reported. Harbor is in growth mode, having just pivoted from pure EDC software to a full-service CRO model in May 2026 and signed its first seven-figure services contract around the same time.
What does Harbor actually sell?: Harbor sells a 21 CFR Part 11-compliant electronic data capture (EDC) system plus, since May 2026, full-service CRO operations including site monitoring, query resolution, and data management, layering AI automation on top of a regulated system of record.

Timeline

2026-05-29Harbor relaunches as full-service AI-native CRO, adds monitoring, data management, query resolution
2026-05-29Harbor discloses first full-service CRO contract: $1.93M over three years with public medical-device sponsor
2026-03-16Harbor launches AI system-of-record EDC with Magic Build and Magic Capture features
2026-01-26Unrelated pre-existing company Harbor Clinical's site snapshot recorded, causing entity confusion risk
2024-09-19Unrelated Dallas company also named Harbor raises $7M seed round, causing entity confusion risk
2024-05-16runharbor.com live with EDC product, customer testimonials of 2-day study startup and 9-day EDC delivery

Revision history

27 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

UPS PDD Holdings (Pinduoduo/Temu)Block